Indore Online Journal

The Cystic Fibrosis Market Insights report from DelveInsight provides a thorough understanding of the Cystic Fibrosis Market size by treatment, epidemiology, emerging therapies, Cystic Fibrosis market share of the various therapies, and the current and forecasted Cystic Fibrosis Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.

Cystic Fibrosis: An Overview

Cystic fibrosis (CF) is a life-limiting autosomal recessive genetic disorder that causes severe damage to the lungs and the digestive system with the highest prevalence in Europe, North America, and Australia where the predominant mutation is Phe508del (also known as F508del).

Download a sample copy of Cystic Fibrosis report offering- https://www.delveinsight.com/sample-request/cystic-fibrosis-market

Regions Covered in the Cystic Fibrosis Market Report

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Key Takeaways from Cystic Fibrosis Market Report

• According to DelveInsight’s analysis, CF is more prominent in males in comparison to females.
• As cystic fibrosis is caused by a genetic mutation in the CFTR gene, it can be of multiple types. In 2017, there were 13,321 cases for F508Del homozygous, 12,206 cases for F508Del heterozygous, and 4,611 cases for other mutations that are expected to rise to 22,100; 20,250; and 7,650 cases respectively in 2030 in the US.
• In 2017, there were 13,984 cases in age group of less than 17 years and 16,155 cases in age group of more than 18 years which are expected to rise as 15,000 cases and 35,000 cases respectively in 2030 in US.

Cystic Fibrosis Epidemiology Insights

The epidemiology section covers insights into the historical and current Cystic Fibrosis Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Cystic Fibrosis Treatment Market

Medications used to treat patients with cystic fibrosis may include pancreatic enzyme supplements, multivitamins (particularly fat-soluble vitamins), mucolytics, antibiotics (including inhaled, oral, or parenteral), bronchodilators, anti-inflammatory agents, and CFTR potentiators (e.g., ivacaftor) and correctors (e.g., elexacaftor, lumacaftor, tezacaftor). The drugs marketed for CFTR correctors are TRIKAFTA, SYMDEKO, ORKAMBI and KALYDECO.

Cystic Fibrosis Market Size

As a result of the complex and multi-systemic involvement of cystic fibrosis (CF) and the need for care by specialists, treatment, and follow-up care at specialty centers with multidisciplinary care teams (i.e., cystic fibrosis centers) is recommended. There’s no cure for cystic fibrosis, but medications and other therapies can ease symptoms, reduce complications, and improve quality of life. Close monitoring and early, aggressive intervention are recommended to slow the progression of CF, which can lead to a longer life. Hypertonic saline inhalation has been proposed as a therapy to increase hydration of airway surface liquid in patients with CF. The Pulmonary Therapies Committee of Cystic Fibrosis Foundation recommends long-term use of hypertonic saline for patients with cystic fibrosis aged 6 or older to improve lung function and to reduce the number of exacerbations.

Cystic Fibrosis Market Dynamics

The market has a promising outlook with many emerging therapies. Some of the major players in the global CF market in the late phase of clinical development are Translate Bio, Proteostasis Therapeutics, Vertex Pharmaceuticals Ionis Pharmaceuticals and others.

Cystic Fibrosis Companies

• Vertex Pharmaceuticals
• Translate Bio Inc.
• Proteostasis Therapeutics
• Arrowhead Pharmaceuticals
• ProQR Therapeutics
• Ionis Pharmaceuticals, and several others

Cystic Fibrosis Drugs

• MRT5005
• Nesolicaftor (PTI-428)
• Dirocaftor (PTI-808)
• VX-121
• ARO-ENaC
• Eluforsen, and several others

Read Full Research Report @ https://www.delveinsight.com/sample-request/cystic-fibrosis-market

Cystic Fibrosis Market Drivers

• High number of drugs in the pipeline
• Better diagnostic techniques
• Most frequent mutation
• Increased Research Funding

Cystic Fibrosis Market Barriers

• Treatment Cost
• Rarity of Disease
• Future competition

Table of content

1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis
4. Market Overview at a Glance
5. Disease Background and Overview
6. Patient Journey
7. Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Cystic Fibrosis Market Treatment
11. Marketed Products
12. Emerging Therapies
13. Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/